VPAC receptor mediated tumor cell targeting by protamine based nanoparticles

Journal of Drug Targeting

Volumn 18, Issue 6, 2010, Pages 457-467

  Ortner, Anna ^a   Wernig, Karin ^b   Kaisler, Raphaela ^c   Edetsberger, Michael ^c   Hajos, Franz ^a   Köhler, Gottfried ^d   Mosgoeller, Wilhelm ^a   Zimmer, Andreas ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Institute of Pharmaceutical Sciences   (Austria)

^c OnkoTec GmbH   (Austria)

^d MAX F PERUTZ LABORATORIES   (Austria)

Author keywords

Nanoparticles; Proticles; Tumor cell targeting; Vasoactive intestinal peptide

Indexed keywords

NANOPARTICLE; PROTICLE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; PROTAMINE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL; ANIMAL; ARTERY; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOPLASM; PARTICLE SIZE; PATHOLOGY; SPECTROFLUOROMETRY; TUMOR CELL LINE; VASODILATATION;

ANIMALS; ARTERIES; CELL LINE, TUMOR; DRUG STABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; PROTAMINES; RATS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SPECTROMETRY, FLUORESCENCE; VASOACTIVE INTESTINAL PEPTIDE; VASODILATION;

EID: 77953237505     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903508796     Document Type: Article

References (34)

1. Behr TM, Béhé M, Becker W. (1999). Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med, 43: 268-280.
2. Bhargava S, Licha K, Knaute T, Ebert B, Becker A, Grötzinger C, Hessenius C, Wiedenmann B, Schneider-Mergener J, Volkmer-Engert R. (2002). A complete substitutional analysis of VIP for better tumor imaging properties. J Mol Recognit, 15: 145-153.
3. Boissard C, Marie JC, Hejblum G, Gespach C, Rosselin G. (1986). Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture. Cancer Res, 46: 4406-4413.
4. Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyüksel H. (2003). VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release, 91: 123-133.
5. Gozes I, Fridkinb M, Hill JM, Brenneman DE. (1999). Pharmaceutical VIP: prospects and problems. Curr Med Chem, 6: 1019-1034.
6. Haberl I, Habringer DS, Andreae F, Artl A, Mosgoeller W. (2006). New nonradioactive technique for vasoactive intestinal peptide-receptor-ligand- binding studies. Ann N Y Acad Sci, 1070: 313-316.
7. Hachisu M, Hiranuma T, Tani S, Iizuka T. (1991). Enzymatic degradation of helodermin and vasoactive intestinal polypeptide. J Pharmacobio-dyn, 14: 126-131.
8. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. (2000). Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem, 7: 971-994.
9. Izzo RS, Scipione RA, Pellecchia C, Lokchander RS. (1991). Binding and internalization of VIP in rat intestinal epithelial cells. Regul Pept, 33: 21-30.
10. Junghans M, Kreuter J, Zimmer A. (2000). Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res, 28: E45.
11. Kostarelos K, Lacerda L, Pastorin G, Wu W, Wieckowski S, Luangsivilay J, Godefroy S, Pantarotto D, Briand JP, Muller S, Prato M, Bianco A. (2007). Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol, 2: 108-113.
12. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. (2004). Peptide receptor radionuclide therapy. Ann N Y Acad Sci, 1014: 234-245.
13. Kurtaran A, Leimer M, Kaserer K, Yang Q, Angelberger P, Niederle B, Virgolini I. (1996). Combined use of 111In-DTPA-DPhe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl Med Biol, 23: 503-507.
14. Laburthe M, Couvineau A, Marie JC. (2002). VPAC receptors for VIP and PACAP. Recept Channels, 8: 137-153.
15. Lilly CM, Drazen JM, Shore SA. (1993). Peptidase modulation of airway effects of neuropeptides. Proc Soc Exp Biol Med, 203: 388-404.
16. Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A. (2005). Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Eur J Pharm Biopharm, 59: 419-429.
17. Moody TW, Czerwinski G, Tarasova NI, Moody DL, Michejda CJ. (2004). The development of VIP-ellipticine conjugates. Regul Pept, 123: 187-192.
18. Ou X, Tan T, He L, Li Y, Li J, Kuang A. (2005). Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor. Cancer Gene Ther, 12: 313-320.
19. Raderer M, Kurtaran A, Leimer M, Angelberger P, Niederle B, Vierhapper H, Vorbeck F, Hejna MH, Scheithauer W, Pidlich J, Virgolini I. (2000). Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPAD-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol, 18: 1331-1336.
20. Refai E, Jonsson C, Andersson M, Jacobsson H, Larsson S, Kogner P, Hassan M. (1999). Biodistribution of liposomal 131I-VIP in rat using gamma camera. Nucl Med Biol, 26: 931-936.
21. Reubi C, Gugger M, Waser B. (2002). Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging, 29: 855-862.
22. Reubi JC. (2003). Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev, 24: 389-427.
23. Said SI, Mutt V. (1970). Polypeptide with broad biological activity: isolation from small intestine. Science, 169: 1217-1218.
24. Schwille P, Haupts U, Maiti S, Webb WW. (1999). Molecular dynamics in living cells observed by fluorescence correlation spectroscopy with one- and two-photon excitation. Biophys J, 77: 2251-2265.
25. Shahbazian A, Baykuscheva-Gentcheva T, Petkov V, Hoeger H, Painsipp E, Holzer P, Mosgoeller W. (2007). Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery. Reg Peptides, 139: 102-108.
26. Shetzline MA, Walker JK, Valenzano KJ, Premont RT. (2002). Vasoactive intestinal polypeptide type-1 receptor regulation. Desensitization, phosphorylation, and sequestration. J Biol Chem, 277: 25519-25526.
27. Stark B, Debbage P, Andreae F, Mosgoeller W, Prassl R. (2007). Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim Biophys Acta, 1768: 705-714.
28. Tam EK, Franconi GM, Nadel JA, Caughey GH. (1990). Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. Am J Respir Cell Mol Biol, 2: 449-452.
29. Virgolini I. (1997). Mack Forster Award Lecture. Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients. Eur J Clin Invest, 27: 793-800.
30. Virgolini I, Kurtaran A, Leimer M, Kaserer K, Peck-Radosavljevic M, Angelberger P, Hübsch P, Dvorak M, Valent P, Niederle B. (1998). Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. J Nucl Med, 39: 1575-1579. (Pubitemid 28459890)
31. Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P. (1995). Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med, 36: 1732-1739.
32. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P. (1996). 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol, 23: 685-692.
33. Wernig K, Griesbacher M, Andreae F, Hajos F, Wagner J, Mosgoeller W, Zimmer A. (2008). Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J Control Release, 130: 192-198.
34. Weyermann J, Lochmann D, Georgens C, Zimmer A. (2005). Albuminprotamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect. Eur J Pharm Biopharm, 59: 431-438.